Literature DB >> 7815481

Recombinant mink cell focus-inducing virus and long terminal repeat alterations accompany the increased leukemogenicity of the Mo+PyF101 variant of Moloney murine leukemia virus after intraperitoneal inoculation.

B Belli1, A Patel, H Fan.   

Abstract

We recently showed that different routes of inoculation affect the leukemogenicity of the Mo+PyF101 variant of Moloney murine leukemia virus (M-MuLV). Intraperitoneal (i.p.) inoculation of neonatal mice with Mo+PyF101 M-MuLV greatly enhanced its leukemogenicity compared with subcutaneous (s.c.) inoculation. We previously also suggested that the leukemogenicity defect of Mo+PyF101 M-MuLV when inoculated s.c. may result from the inability of this virus to form env gene recombinant (mink cell focus-inducing [MCF]) virus. In this study, virus present in end-stage tumors and in preleukemic animals inoculated i.p. by Mo+PyF101 M-MuLV was characterized. In contrast to s.c. inoculation, all tumors from i.p.-inoculated mice contained high levels of recombinant MCF virus. Furthermore, Southern blot analyses demonstrated that the majority of the tumors contained altered Mo+PyF101 M-MuLV long terminal repeats. The U3 regions from several tumors with altered long terminal repeats were cloned by PCR amplification. Sequence analyses indicated that the M-MuLV 75-bp tandem repeat in the enhancer region was triplicated. This amplification was also previously observed in mice infected s.c. with a pseudotypic mixture of Mo+PyF101 M-MuLV and Mo+PyF101 MCF virus. The enhancer triplication was an early event, and it occurred within 2 weeks postinfection. Recombinant MCF viruses were not detected by Southern blot analyses until 4 weeks postinfection. Thus, the M-MuLV enhancer triplication event was initially important for efficient propagation of ecotropic Mo+PyF101 M-MuLV. The increased leukemogenicity following i.p. inoculation could be explained if the triplication enhances Mo+PyF101 M-MuLV replication in the bone marrow and bone marrow infection is required for recombinant MCF virus formation.

Entities:  

Mesh:

Year:  1995        PMID: 7815481      PMCID: PMC188674     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

2.  Suppression of leukaemia virus pathogenicity by polyoma virus enhancers.

Authors:  B Davis; E Linney; H Fan
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

3.  Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat.

Authors:  J Lenz; D Celander; R L Crowther; R Patarca; D W Perkins; W A Haseltine
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

4.  Characterization of a preleukemic state induced by Moloney murine leukemia virus: evidence for two infection events during leukemogenesis.

Authors:  B R Davis; B K Brightman; K G Chandy; H Fan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  Rearrangements and insertions in the Moloney murine leukemia virus long terminal repeat alter biological properties in vivo and in vitro.

Authors:  H Fan; S Mittal; H Chute; E Chao; P K Pattengale
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

6.  Proliferation of infected lymphoid precursors before Moloney murine leukemia virus-induced T-cell lymphoma.

Authors:  T G Storch; P Arnstein; V Manohar; W M Leiserson; T M Chused
Journal:  J Natl Cancer Inst       Date:  1985-01       Impact factor: 13.506

7.  Effects of nonleukemogenic and wild-type Moloney murine leukemia virus on lymphoid cells in vivo: identification of a preleukemic shift in thymocyte subpopulations.

Authors:  B R Davis; K G Chandy; B K Brightman; S Gupta; H Fan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

8.  Addition of substitution of simian virus 40 enhancer sequences into the Moloney murine leukemia virus (M-MuLV) long terminal repeat yields infectious M-MuLV with altered biological properties.

Authors:  R Hanecak; P K Pattengale; H Fan
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

9.  Role for the 3' end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses.

Authors:  P A Chatis; C A Holland; J W Hartley; W P Rowe; N Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

10.  Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation.

Authors:  G Selten; H T Cuypers; M Zijlstra; C Melief; A Berns
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

View more
  10 in total

1.  Appearance of mink cell focus-inducing recombinants during in vivo infection by moloney murine leukemia virus (M-MuLV) or the Mo+PyF101 M-MuLV enhancer variant: implications for sites of generation and roles in leukemogenesis.

Authors:  J K Lander; B Chesebro; H Fan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Replication of Mus dunni endogenous retrovirus depends on promoter activation followed by enhancer multimerization.

Authors:  G Wolgamot; A D Miller
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Sequence analysis of porcine endogenous retrovirus long terminal repeats and identification of transcriptional regulatory regions.

Authors:  Carolyn A Wilson; Sabahat Laeeq; Armin Ritzhaupt; Winston Colon-Moran; Fayth K Yoshimura
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Tandemization of a subregion of the enhancer sequences from SRS 19-6 murine leukemia virus associated with T-lymphoid but not other leukemias.

Authors:  S W Granger; L M Bundy; H Fan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  Introduction of a cis-acting mutation in the capsid-coding gene of moloney murine leukemia virus extends its leukemogenic properties.

Authors:  M Audit; J Déjardin; B Hohl; C Sidobre; T J Hope; M Mougel; M Sitbon
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.

Authors:  C R Starkey; P A Lobelle-Rich; S W Granger; S Granger; B K Brightman; H Fan; L S Levy
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Mapping of a major osteomagenic determinant of murine leukemia virus RFB-14 to non-long terminal repeat sequences.

Authors:  M Ostergaard; L Pedersen; J Schmidt; A Luz; J Lovmand; V Erfle; F S Pedersen; P G Strauss
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.

Authors:  S Ethelberg; B Hallberg; J Lovmand; J Schmidt; A Luz; T Grundström; F S Pedersen
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Moloney murine leukemia virus-induced preleukemic thymic atrophy and enhanced thymocyte apoptosis correlate with disease pathogenicity.

Authors:  C Bonzon; H Fan
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer.

Authors:  D F Purcell; C M Broscius; E F Vanin; C E Buckler; A W Nienhuis; M A Martin
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.